{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:03:59Z","timestamp":1787169839405,"version":"build-2736575974"},"reference-count":131,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.jaad.2008.12.031","type":"journal-article","created":{"date-parts":[[2009,4,3]],"date-time":"2009-04-03T04:31:12Z","timestamp":1238733072000},"page":"1001-1017","source":"Crossref","is-referenced-by-count":188,"title":["Treatments for psoriasis and the risk of malignancy"],"prefix":"10.1016","volume":"60","author":[{"given":"Rita V.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily N.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Weinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2008.12.031_bib1","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1: Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib2","first-page":"280","article-title":"The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey","volume":"137","author":"Kruger","year":"2001","journal-title":"Arch Dermatol"},{"issue":"Suppl 2","key":"10.1016\/j.jaad.2008.12.031_bib3","doi-asserted-by":"crossref","first-page":"ii30","DOI":"10.1136\/ard.2004.031120","article-title":"Psoriasis pathophysiology: current concepts of pathogenesis","volume":"64","author":"Krueger","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2008.12.031_bib4","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1346-8138.1999.tb02021.x","article-title":"Elevated B-lymphocyte levels in lesional tissue of non-arthritic psoriasis","volume":"26","author":"Mahmoud","year":"1999","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0923-1811(91)90022-P","article-title":"Mononuclear cell bound CD23 is elevated in both atopic dermatitis and psoriasis","volume":"2","author":"M\u00fcller","year":"1991","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2008.12.031_bib6","first-page":"778","article-title":"The risk of malignancy associated with psoriasis","volume":"137","author":"Margolis","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib7","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1001\/archderm.139.11.1425","article-title":"Lymphoma rates are low but increased in patients with psoriasis","volume":"139","author":"Gelfand","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib8","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1038\/sj.jid.5700410","article-title":"The risk of lymphoma in patients with psoriasis","volume":"126","author":"Gelfand","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib9","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJM197412052912301","article-title":"Photochemotherapy of psoriasis with oral methoxsalen and long wave ultraviolet light","volume":"291","author":"Parrish","year":"1974","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2008.12.031_bib10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1011-1344(00)00024-5","article-title":"Photoimmunology, DNA repair and photocarcinogenesis","volume":"54","author":"Berneburg","year":"2000","journal-title":"J Photochem Photobiol"},{"key":"10.1016\/j.jaad.2008.12.031_bib11","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1093\/jnci\/53.5.1333","article-title":"Antigenicity of murine skin tumors induced by ultraviolet light","volume":"53","author":"Kripke","year":"1974","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jaad.2008.12.031_bib12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0065-230X(08)60239-0","article-title":"Immunology mechanisms in UV radiation carcinogenesis","volume":"34","author":"Kripke","year":"1981","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.jaad.2008.12.031_bib13","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1046\/j.1610-0387.2003.02522.x","article-title":"[Effects of ultraviolet radiation on immunity]","volume":"2","author":"Schwarz","year":"2003","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaad.2008.12.031_bib14","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/jnci\/90.17.1278","article-title":"Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer","volume":"90","author":"Stern","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jaad.2008.12.031_bib15","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/1523-1747.ep12522663","article-title":"The PUVA lentigo: an analysis of predisposing factors","volume":"81","author":"Rhodes","year":"1983","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2133.1987.tb05805.x","article-title":"Cutaneous and ocular side effects of oral photochemotherapy: the results of an 8-year follow up study","volume":"116","author":"Cox","year":"1987","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib17","first-page":"761","article-title":"The PUVA-induced pigmented macule: a lentiginous proliferation of large, sometimes cytologically atypical melanocytes","volume":"13","author":"Rhodes","year":"1985","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib18","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2133.1986.tb02838.x","article-title":"Longitudinal melanonychia during photochemotherapy","volume":"114","author":"MacDonald","year":"1986","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib19","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1056\/NEJM199704103361501","article-title":"Malignant melanoma in patients treated for psoriasis with methoxsalen (Psoralen) and ultraviolet A radiation (PUVA)","volume":"336","author":"Stern","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2008.12.031_bib20","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/000155599750011778","article-title":"Eye and hair colour, skin type and constitutive skin pigmentation as risk factors for basal cell carcinoma and cutaneous malignant melanoma: a Danish case-control study","volume":"79","author":"Lock-Anderson","year":"1999","journal-title":"Acta Derm Venerol"},{"key":"10.1016\/j.jaad.2008.12.031_bib21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2165\/00002018-199920040-00001","article-title":"Risk of melanoma with psoralen\/ultraviolet A therapy for psoriasis, do the known risks now outweigh the benefits","volume":"20","author":"Lindelof","year":"1999","journal-title":"Drug Safety"},{"key":"10.1016\/j.jaad.2008.12.031_bib22","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1002\/1097-0142(19940601)73:11<2759::AID-CNCR2820731118>3.0.CO;2-C","article-title":"The carcinogenic risk of treatments for severe psoriasis","volume":"73","author":"Stern","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2008.12.031_bib23","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S0140-6736(01)06179-7","article-title":"Squamous-cell cancer of the skin in patients given PUVA and cyclosporine: nested cohort crossover study","volume":"358","author":"Marcil","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2008.12.031_bib24","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1067\/S0190-9622(03)01587-1","article-title":"Oral retinoid use reduced cutaneous squamous cell carcinoma risk in patients with psoriasis treat with psoralen-UVA: a nested cohort study","volume":"49","author":"Nijsten","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib25","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/archderm.142.9.1132","article-title":"Lymphoma risk in psoriasis","volume":"142","author":"Stern","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2133.1988.tb07096.x","article-title":"A new development in UVB phototherapy of psoriasis","volume":"119","author":"van Weelden","year":"1988","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib27","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0190-9622(99)70090-3","article-title":"Phototherapy for atopic eczema, with narrowband UVB","volume":"40","author":"Grundmann-Kollmann","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib28","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1067\/mjd.2001.114752","article-title":"Narrow-band ultraviolet B is a useful and well-tolerated treatment for vitiligo","volume":"44","author":"Scherschun","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib29","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1751-1097.1993.tb04946.x","article-title":"Comparative potency of broadband and narrowband phototherapy sources to induce edema, sunburn cells, and urocanic acid photoisomerization in hairless mouse skin","volume":"58","author":"Gibbs","year":"1993","journal-title":"Photochem Photobiol"},{"key":"10.1016\/j.jaad.2008.12.031_bib30","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1080\/00015550410026948","article-title":"No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: a first retrospective study","volume":"84","author":"Weischer","year":"2004","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2008.12.031_bib31","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1002\/1097-0142(19940601)73:11<2759::AID-CNCR2820731118>3.0.CO;2-C","article-title":"The carcinogenic risk of treatments for severe psoriasis","volume":"73","author":"Stern","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2008.12.031_bib32","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1365-2133.2005.06537.x","article-title":"The photocarcinogenic risk of narrowband UVB (TL-01) phototherapy: early follow-up data","volume":"152","author":"Man","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib33","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.0022-202X.2005.23618.x","article-title":"High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet A-treated patients","volume":"124","author":"Lim","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib34","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1365-2133.2008.08776.x","article-title":"Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy","volume":"159","author":"Hearn","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib35","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/1097-0142(19820901)50:5<869::AID-CNCR2820500511>3.0.CO;2-V","article-title":"Methotrexate used for psoriasis and the risk of noncutaneous or cutaneous malignancy","volume":"50","author":"Stern","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2008.12.031_bib36","first-page":"322","article-title":"Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication","volume":"34","author":"Hoshida","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib37","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/jama.232.4.359","article-title":"Is methotrexate therapy for psoriasis carcinogenic?","volume":"232","author":"Bailin","year":"1975","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2008.12.031_bib38","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/1097-0142(19820901)50:5<869::AID-CNCR2820500511>3.0.CO;2-V","article-title":"Methotrexate used for psoriasis and the risk of noncutaneous or cutaneous malignancy","volume":"50","author":"Stern","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2008.12.031_bib39","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1378\/chest.123.6.2150","article-title":"Methotrexate-induced pulmonary lymphoma","volume":"123","author":"Ebeo","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.jaad.2008.12.031_bib40","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/archderm.133.7.867","article-title":"Epstein-Barr virus-associated lymphoproliferative disorders during methotrexate therapy for psoriasis","volume":"133","author":"Paul","year":"1997","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib41","doi-asserted-by":"crossref","first-page":"379","DOI":"10.4103\/0378-6323.42919","article-title":"Hodgkin's lymphoma in a patient of psoriasis treated with long-term, low-dose methotrexate therapy","volume":"74","author":"Khopkar","year":"2008","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaad.2008.12.031_bib42","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1440-1843.2007.01139.x","article-title":"Pulmonary lymphoma developed during long-term methotrexate therapy for psoriasis","volume":"12","author":"Suzuki","year":"2007","journal-title":"Respirology"},{"key":"10.1016\/j.jaad.2008.12.031_bib43","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archderm.133.7.903","article-title":"Lymphomas during long-term methotrexate therapy","volume":"133","author":"Kamel","year":"1997","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib44","first-page":"1444","article-title":"Association of methotrexate, rheumatoid arthritis, and melanoma in two patients","volume":"24","author":"Jeannou","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib45","first-page":"507","article-title":"Malignant melanoma in patients with rheumatoid arthritis","volume":"16","author":"Ishiyama","year":"1998","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib46","first-page":"2282","article-title":"Multiple malignant melanomas in patients with RA treated with methotrexate","volume":"25","author":"Potter","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib47","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/art.23716","article-title":"Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate","volume":"59","author":"Buchbinder","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2008.12.031_bib48","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJM197909063011015","article-title":"Cyclosporine A for psoriasis","volume":"301","author":"Mueller","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2008.12.031_bib49","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1001\/jama.256.22.3110","article-title":"Cyclosporine improves psoriasis in a double-blind study","volume":"256","author":"Ellis","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2008.12.031_bib50","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/bmj.293.6549.731","article-title":"Clearance of psoriasis with low dose cyclosporine","volume":"293","author":"Griffiths","year":"1986","journal-title":"BMJ"},{"issue":"Suppl 95","key":"10.1016\/j.jaad.2008.12.031_bib51","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/03009749209101481","article-title":"Safety aspects of the long-term cyclosporine A therapy","volume":"21","author":"Kurki","year":"1992","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib52","first-page":"23","article-title":"The problem of cancer in organ transplant recipients: an overview","volume":"4","author":"Penn","year":"1994","journal-title":"Transplant Sci"},{"key":"10.1016\/j.jaad.2008.12.031_bib53","first-page":"1129","article-title":"Risk indications of de novo malignancy in renal transplant recipients","volume":"9","author":"Sloan","year":"1997","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jaad.2008.12.031_bib54","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0896-8411(89)80010-1","article-title":"The risk of neoplasms in patients treated with cyclosporine A","volume":"2","author":"Cockburn","year":"1989","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jaad.2008.12.031_bib55","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/0190-9622(92)70117-X","article-title":"The development of B-cell lymphoma in a patient with psoriasis treated with cyclosporine","volume":"26","author":"Koo","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib56","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1523-1747.2003.12040.x","article-title":"Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study","volume":"120","author":"Paul","year":"2003","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib57","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2340\/00015555-0033","article-title":"Adult T-cell lymphoma\/leukaemia developing in a patient with psoriasis treated with long-term cyclosporine","volume":"86","author":"Watabe","year":"2006","journal-title":"Acta Derm Venerol"},{"issue":"Suppl","key":"10.1016\/j.jaad.2008.12.031_bib58","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.jaad.2004.06.043","article-title":"Epstein-Barr virus-associated lymphoproliferative disease after long-standing cyclosporine therapy for psoriasis: a case of spontaneous regression","volume":"52","author":"Lelievre","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib59","first-page":"680","article-title":"Early and explosive development of nodular basal cell carcinoma and multiple keratoacanthomas in psoriasis patients treated with cyclosporine","volume":"3","author":"Lain","year":"2004","journal-title":"J Drug Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib60","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000069946","article-title":"Primary cutaneous CD30+ large T-cell lymphoma in a patient with psoriasis treated with cyclosporine","volume":"206","author":"Corazza","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2008.12.031_bib61","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1046\/j.1365-2133.2003.05384.x","article-title":"CD30+ T-cell lymphoma in a patient with psoriasis treated with cyclosporine and infliximab","volume":"149","author":"Mahe","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib62","first-page":"271","article-title":"Two cases of chronic lymphoproliferative disorders in psoriatic patients treated with cyclosporine: hairy cell leukemia and Waldenstrom macroglobulinemia","volume":"15","author":"Fozza","year":"2005","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib63","first-page":"189","article-title":"Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use","volume":"4","author":"Behnam","year":"2005","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib64","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/1523-1747.ep12610346","article-title":"Treatment of psoriasis with oral mycophenolic acid","volume":"65","author":"Jones","year":"1975","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib65","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0190-9622(79)80097-3","article-title":"Efficacy of mycophenolic acid for the treatment of psoriasis","volume":"1","author":"Gomez","year":"1979","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib66","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.jaad.2008.12.031_bib67","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1001\/archderm.113.9.1203","article-title":"Mycophenolic acid for psoriasis","volume":"113","author":"Lynch","year":"1977","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib68","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S0190-9622(87)70285-0","article-title":"Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety","volume":"17","author":"Epinette","year":"1987","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib69","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.healun.2006.06.010","article-title":"Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation","volume":"25","author":"O'Neill","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jaad.2008.12.031_bib70","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.healun.2005.02.002","article-title":"Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients","volume":"24","author":"Eisen","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jaad.2008.12.031_bib71","unstructured":"Roche Transplantation Cellcept [package insert]. Available at: http:\/\/www.rochetransplant.com\/product\/cellcept\/default.aspx. Accessed October 2008."},{"key":"10.1016\/j.jaad.2008.12.031_bib72","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1093\/ndt\/gfg250","article-title":"The long-term effect of switching from cyclosporine A to mycophenolate mofetil in chronic renal graft dysfunction compared with conventional management","volume":"18","author":"Francois","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jaad.2008.12.031_bib73","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1046\/j.1365-2133.2000.03670.x","article-title":"Change of treatment from cyclosporine and mycophenolate mofetil in severe psoriasis","volume":"143","author":"Davison","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib74","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.sder.2006.12.002","article-title":"Complications and adverse reactions in the use of newer biologic agents","volume":"26","author":"Callen","year":"2007","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.jaad.2008.12.031_bib75","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/j.yexcr.2007.03.027","article-title":"The inhibition of TNF-\u03b1 anti-tumoral properties by clocking antibodies promotes tumor growth in a rat model","volume":"313","author":"Larmonier","year":"2007","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.jaad.2008.12.031_bib76","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/art.22864","article-title":"Biologic treatment of rheumatoid arthritis and risk of malignancy: analyses from a large US observational study","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arch Rheum"},{"key":"10.1016\/j.jaad.2008.12.031_bib77","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/BOR.0b013e3282f7c706","article-title":"Malignancy and biologic therapy in rheumatoid arthritis","volume":"20","author":"Askling","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib78","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/art.21869","article-title":"Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial","volume":"54","author":"Stone","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2008.12.031_bib79","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1164\/rccm.200607-995OC","article-title":"The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease","volume":"175","author":"Rennard","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaad.2008.12.031_bib80","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systemic review and meta-analysis of rare harmful effects in randomized control trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2008.12.031_bib81","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/eji.200323586","article-title":"Alefacept selectively promotes NK cell-medicated deletion of CD450RO+ human T cells","volume":"33","author":"Cooper","year":"2003","journal-title":"Eur J Immunol"},{"issue":"2 Suppl. 2","key":"10.1016\/j.jaad.2008.12.031_bib82","first-page":"AB191","article-title":"Assessment and tracking of long-term alefacept safety (ATLAS): analysis of data from approximately 1,200 patients","volume":"56","author":"Krell","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 2","key":"10.1016\/j.jaad.2008.12.031_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1468-3083.17.s2.1.x","article-title":"The immunological basis of psoriasis","volume":"17","author":"Griffiths","year":"2003","journal-title":"J Eur Acad Dermatol Venerol"},{"key":"10.1016\/j.jaad.2008.12.031_bib84","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1159\/000077660","article-title":"T cell modulation for the treatment of chronic plaque psoriasis with efalizumab: mechanism of action","volume":"208","author":"Jullien","year":"2004","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2008.12.031_bib85","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/1523-1747.ep12335758","article-title":"T lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice","volume":"109","author":"Gilhar","year":"1997","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib86","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/archderm.138.5.591","article-title":"Psoriasis as a model for T cell mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody","volume":"138","author":"Gottlieb","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib87","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0190-9622(88)70145-0","article-title":"Immunologic mechanisms in psoriasis","volume":"18","author":"Gottlieb","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib88","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1172\/JCI118989","article-title":"Dermal injection of immunocytes induces psoriasis","volume":"98","author":"Wrone-Smith","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaad.2008.12.031_bib89","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1067\/mjd.2000.107945","article-title":"Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of pilot, multicenter, multiple-dose, placebo-controlled study","volume":"43","author":"Gottlieb","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib90","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000095037","article-title":"A review of malignancies observed during efalizumab (Raptiva\u00ae) clinical trials for plaque psoriasis","volume":"213","author":"Leonardi","year":"2006","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2008.12.031_bib91","first-page":"646","article-title":"Efalizumab-associated lymphoproliferative disease","volume":"6","author":"Bommakanti","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib92","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jaad.2005.02.008","article-title":"Cervical cancer in a woman associated with long-term efalizumab therapy","volume":"53","author":"Morse","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib93","first-page":"699","article-title":"Elevated tumor necrosis factor-alpha biological activity in psoriatic skin lesions","volume":"64","author":"Ettehadi","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2008.12.031_bib94","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1001\/archderm.140.2.218","article-title":"Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis","volume":"140","author":"Krueger","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib95","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/09546630410017275","article-title":"A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab, and adalimumab","volume":"15","author":"Scheinfeld","year":"2004","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.jaad.2008.12.031_bib96","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2008.12.031_bib97","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1517\/14712598.5.11.1491","article-title":"Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis","volume":"5","author":"Mease","year":"2005","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jaad.2008.12.031_bib98","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2008.12.031_bib99","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1001\/jama.296.18.2201-b","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies","volume":"296","author":"Okada","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2008.12.031_bib100","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2133.2008.08664.x","article-title":"Gastric MALT lymphoma in a patient receiving infliximab for psoriasis","volume":"159","author":"Girard","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib101","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.10679","article-title":"Tumor necrosis factor antagonist therapy and lymphoma development","volume":"46","author":"Brown","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2008.12.031_bib102","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/ard.2004.033241","article-title":"Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumor necrosis factor antagonists","volume":"64","author":"Askling","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2008.12.031_bib103","first-page":"2130","article-title":"Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors","volume":"32","author":"Chakravarty","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib104","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1067\/mjd.2001.117725","article-title":"Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor \u03b1 receptor IgG1-Fc fusion complex therapy","volume":"45","author":"Smith","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib105","first-page":"575","article-title":"Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab","volume":"50","author":"Easer","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib106","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1136\/ard.2004.033993","article-title":"Risks of solid cancer in patients with rheumatoid arthritis and after treatment with tumor necrosis factor antagonists","volume":"64","author":"Askling","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2008.12.031_bib107","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s10067-006-0454-4","article-title":"Atypical carcinoid tumor of the thymus ectopic ACTH production developed during the course of etanercept treatment\u2014case report","volume":"26","author":"Simsek","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib108","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1067\/S0190-9622(03)00811-9","article-title":"Etanercept and squamous cell carcinoma","volume":"49","author":"Burge","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib109","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jaad.2004.07.031","article-title":"Rapid onset of cutaneous squamous cell carcinoma of the penis in a patient with psoriasis on etanercept therapy","volume":"51","author":"Fryrear","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib110","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/j.1365-2133.2007.08182.x","article-title":"The rapid onset of multiple squamous cell carcinomas during etanercept treatment for psoriasis","volume":"157","author":"Ly","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib111","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaad.2006.12.024","article-title":"Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies","volume":"56","author":"Fulchiero","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib112","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jaad.2006.06.032","article-title":"Acute myelogenous leukemia in a patient receiving etanercept for psoriasis","volume":"56","author":"Bachmeyer","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib113","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/ajh.20926","article-title":"TNF-\u03b1 inhibitor etanercept and hematologic malignancies: report of a case and review of the literature","volume":"82","author":"Nair","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaad.2008.12.031_bib114","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2165\/00002018-200831050-00013","article-title":"TNF-\u03b1 inhibitors and leukemia: international pharmacovigilance reports","volume":"31","author":"Meyboom","year":"2008","journal-title":"Drug Safety"},{"key":"10.1016\/j.jaad.2008.12.031_bib115","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1746-1596-3-13","article-title":"A transient benign lymph node-based proliferation of T-cells stimulating non-Hodgkin lymphoma in a patient with psoriasis treated with tumor necrosis factor alpha and CD11a antagonists","volume":"3","author":"Hurley","year":"2008","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.jaad.2008.12.031_bib116","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1046\/j.1365-2133.2003.05384.x","article-title":"CD30+ T-cell lymphoma in a patient with psoriasis treated with cyclosporine and infliximab","volume":"149","author":"Mahe","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib117","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener's granulomatosis","volume":"352","author":"Wegener's Granulomatosis Etanercept Trial (WGET) Research Group","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2008.12.031_bib118","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2133.2005.06893.x","article-title":"British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005","volume":"153","author":"Smith","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib119","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.2174\/092986706776360879","article-title":"Targeting cytokines of the interleukin-12 family in autoimmunity","volume":"13","author":"Kang","year":"2006","journal-title":"Current Med Chem"},{"key":"10.1016\/j.jaad.2008.12.031_bib120","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1146\/annurev.immunol.22.012703.104758","article-title":"Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation","volume":"25","author":"Kastelstein","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaad.2008.12.031_bib121","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/jid.2008.85","article-title":"T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis","volume":"128","author":"Blauvelt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib122","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature04808","article-title":"IL-23 promotes tumor incidence and growth","volume":"442","author":"Langowski","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2008.12.031_bib123","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.4049\/jimmunol.165.5.2665","article-title":"The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent","volume":"165","author":"Smyth","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2008.12.031_bib124","unstructured":"US Food and Drug Administration CDER 2008 Meeting Documents, Dermatologic & Ophthalmic Drugs Advisory Committee. June 17 and 18, 2008; transcripts."},{"key":"10.1016\/j.jaad.2008.12.031_bib125","first-page":"1213","article-title":"Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis","volume":"32","author":"Jacobsson","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib126","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1002\/art.22809","article-title":"Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor \u03b1 therapy","volume":"56","author":"Dixon","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2008.12.031_bib127","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/ard.2006.062497","article-title":"Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis","volume":"66","author":"Jacobsson","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2008.12.031_bib128","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/ard.2004.030528","article-title":"Tumour necrosis factors do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas","volume":"64","author":"Geborek","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2008.12.031_bib129","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.jaad.2005.09.015","article-title":"Reversal of multifocal cutaneous lymphoproliferative disease associated with Epstein-Barr virus after withdrawal of methotrexate therapy for rheumatoid arthritis","volume":"57","author":"Maruani","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib130","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jaad.2006.09.011","article-title":"Methotrexate-associated lymphoproliferative disorder in a patient with rheumatoid arthritis presenting in the skin","volume":"56","author":"Clarke","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.12.031_bib131","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/ajh.21003","article-title":"Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection","volume":"82","author":"Miyazaki","year":"2007","journal-title":"Am J Hematol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962209000115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962209000115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T14:52:54Z","timestamp":1684939974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962209000115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":131,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S0190962209000115"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2008.12.031","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}